Why haven't we seen a race to the bottom in SaaS pricing?

The “race to the bottom” assumption misses how SaaS is actually bought

In a true commodity market, products are interchangeable, switching is easy, and buyers can compare on price alone. Most SaaS markets don’t look like that—especially in medtech. Even when two tools appear similar on a feature checklist, buyers experience them differently in implementation, reliability, integrations, support, and risk.

Medtech SaaS (digital health, clinical workflow, imaging AI platforms, device software, remote monitoring dashboards) is rarely purchased like “$9.99/month for storage.” It’s purchased as a risk-managed operational change. That shifts the decision from “cheapest wins” to “lowest total cost of ownership and lowest clinical/business risk wins.”

Business jargon translation: total cost of ownership (TCO) means the full cost over time—license + implementation + training + integration + downtime + support + compliance overhead + switching later.

Four forces that keep SaaS prices from collapsing

1) Switching costs are real (and often bigger than the subscription)

SaaS vendors can keep pricing power when customers can’t easily switch. In medtech, switching costs are amplified by:

• Integrations (EHR, PACS, LIS, billing, SSO, device fleets). Even “simple” HL7/FHIR work can be slow because hospital IT bandwidth is limited.
• Workflow retraining for clinicians and staff. A tool that touches triage, documentation, or imaging reads creates habit change and productivity dips during transition.
• Data migration and auditability. Clinical data retention, provenance, and audit logs matter; moving data isn’t just export/import.
• Validation burden. If the software is part of a regulated process (or is itself Software as a Medical Device), you may need re-validation, updated SOPs, and sometimes IRB considerations for studies.

Even if a competitor is 30% cheaper, the buyer may rationally stick with the incumbent because the switching project costs more than the annual license.

2) Differentiation isn’t just features—it’s outcomes, trust, and reliability

Feature parity is common. What’s harder to copy is the system around the product:

• Uptime, latency, and disaster recovery (especially for acute workflows).
• Security posture (SOC 2 reports, pen tests, incident response maturity). These are expensive to build and maintain.
• Clinical/operational support: onboarding, go-live support, and ongoing optimization.
• Evidence: validation studies, real-world performance monitoring, and post-market surveillance processes (when applicable).

In medtech, “trust” is not marketing fluff. A hospital may pay more for a vendor that reduces perceived risk: fewer patient safety concerns, fewer compliance surprises, and fewer escalations to IT/security committees.

3) Price is often anchored to value, not cost

Many SaaS categories price using value-based pricing: charging a fraction of the economic value created (revenue gained, costs avoided, risk reduced). When value is large, prices don’t need to converge to marginal cost.

Medtech examples where value anchors pricing:

• Revenue capture: tools that improve documentation, coding accuracy, or reduce denials. If a product demonstrably improves collections, it’s priced against that upside.
• Capacity and throughput: reducing length of stay, speeding imaging turnaround, or improving scheduling utilization. Hospitals pay for capacity because it’s scarce.
• Risk reduction: preventing adverse events, reducing readmissions, or improving compliance reporting. Even when ROI is hard to quantify, risk reduction can justify premium pricing.

Important nuance: you don’t need to cite sweeping statistics. You need a credible ROI model for a specific buyer type (e.g., radiology department, revenue cycle, nursing leadership) with assumptions they can validate.

4) Enterprise procurement rewards “safe choices,” not cheapest choices

Hospital procurement is not Amazon. Deals are shaped by committees and risk gates: IT security review, legal, compliance, clinical leadership, sometimes a value analysis committee, and budget owners. This creates a bias toward vendors that look stable and defensible.

Two practical implications:

• Low price can be a negative signal. If you’re dramatically cheaper, buyers may worry you can’t support them, won’t survive, or will cut corners on security/compliance.
• Procurement complexity compresses competition. If only a few vendors can pass security, integration, and reference checks, price competition is limited.

Medtech-specific stabilizers: regulation, reimbursement, and clinical risk

Medtech SaaS often sits near regulated claims or regulated workflows. That creates barriers that prevent “anyone can clone it and undercut.”

Regulatory pathway can create durable differentiation

If your product is Software as a Medical Device (SaMD) or part of a device system, regulatory work can be a moat. The exact FDA pathway depends on intended use and risk: 510(k) (substantial equivalence), De Novo (new low-to-moderate risk category), or PMA (high risk). The point isn’t that clearance guarantees pricing power—it’s that it raises the cost and time for competitors to credibly match your claims.

Also, regulated products carry ongoing obligations (quality management system, change control, post-market monitoring). Those costs are real and tend to keep pricing above “commodity SaaS.”

Reimbursement and CPT dynamics shift the pricing conversation

When a product’s adoption is tied to reimbursement (e.g., remote patient monitoring programs, certain diagnostics, care management workflows), buyers care about whether the workflow can be executed reliably and compliantly. If your software helps them operationalize reimbursable services, pricing is often anchored to program economics rather than software cost.

Translation: if a clinic can’t consistently deliver the service (documentation, time tracking, patient consent, device logistics), the reimbursement doesn’t materialize. They’ll pay more for software that makes the program run.

Clinical risk makes “good enough” unacceptable

In many SaaS categories, a few bugs are tolerable. In clinical settings, errors can create patient harm, malpractice exposure, or regulatory scrutiny. That pushes buyers toward vendors with strong QA, monitoring, explainability (for AI), and support. Those capabilities cost money and support premium pricing.

Why competition often shows up as packaging, not price cuts

Instead of slashing list price, SaaS companies usually compete by changing packaging (what’s included) and pricing metrics (how usage is measured). This preserves headline pricing while letting vendors target different segments.

Common patterns in medtech SaaS:

• Land-and-expand: start with one department/site, then expand across sites or service lines. Initial pricing may be discounted, but expansion restores margin.
• Tiered plans: basic vs enterprise features (audit logs, SSO, advanced analytics, admin controls).
• Implementation fees: one-time services that fund onboarding and integrations (often necessary in hospitals).
• Outcome-based pilots: a time-bound pilot with success criteria; not “cheap forever,” but “prove value, then scale.”

Business jargon translation: pricing metric is the unit you charge on—per clinician, per bed, per study, per device, per site, per message, etc. Choosing the right metric can reduce price pressure because it aligns with the buyer’s value driver.

Founder takeaway: if you’re seeing price pressure, it’s usually a positioning problem

When founders complain “competitors are cheaper,” the underlying issue is often that the buyer perceives the product as interchangeable. In medtech, you can usually escape price wars by tightening three things:

1. ICP clarity (ideal customer profile): one buyer type, one workflow, one budget owner.
2. Quantified value story: a simple ROI model tied to that buyer’s KPIs (throughput, denials, staffing, readmissions, time-to-result).
3. Risk-reduction proof: security readiness, clinical validation approach, references, and implementation plan.

If you can’t articulate those, procurement will treat you like a commodity and negotiate you down.

What to do next

• Map your switching costs: list every integration, training step, and validation activity your customer would repeat if they switched. Turn that into a “switching cost narrative” for sales.
• Pick a value-aligned pricing metric: per site, per bed, per study, per device, or per clinician—choose the one that tracks value creation and is easy to forecast.
• Build a one-page ROI model for a single department (e.g., radiology, ICU, revenue cycle). Keep assumptions editable and defensible.
• Prepare for hospital procurement: create a lightweight security/compliance packet (policies, architecture overview, incident response) and an implementation plan with timelines.
• Pressure-test your positioning by comparing against 3 closest alternatives and writing why you win without mentioning features.